Xofigo

Active Ingredient(s): Radium Ra-223 Dichloride
FDA Approved: * May 15, 2013
Pharm Company: * BAYER HLTHCARE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xofigo Overview

Radium-223 (Ra-223, 223Ra) is an isotope of radium with an 11.4-day half-life, in contrast to the more common isotope radium-226, discovered by the Curies, which has a 1601-year half-life. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits. Contents 1 Origin and preparation 2 Medical use 2.1 Mechanism of action 2.2 Clinical trials and FDA...

Read more Xofigo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Radium-223_chloride

Recent Xofigo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Xofigo: (1 result)

Sorted by National Drug Code

• 50419-208 Xofigo 27 Uci/Ml Intravenous Injection by Bayer Healthcare Pharmaceuticals Inc.

Other drugs which contain Radium Ra-223 Dichloride or a similar ingredient: (2 results)

• ALPHARADIN Radium-223 Chloride
• RADIUM RA-223 DICHLORIDE